Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €38.40 EUR
Change Today +0.37 / 0.97%
Volume 176.0K
ORNBV On Other Exchanges
Symbol
Exchange
Helsinki
Helsinki
OTC US
OTC US
Frankfurt
As of 11:29 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

orion oyj-class b (ORNBV) Snapshot

Open
€38.03
Previous Close
€38.03
Day High
€38.49
Day Low
€37.99
52 Week High
07/20/15 - €38.86
52 Week Low
12/16/14 - €24.85
Market Cap
5.4B
Average Volume 10 Days
224.4K
EPS TTM
€1.52
Shares Outstanding
101.6M
EX-Date
03/25/15
P/E TM
25.3x
Dividend
€1.30
Dividend Yield
3.39%
Current Stock Chart for ORION OYJ-CLASS B (ORNBV)

Related News

No related news articles were found.

orion oyj-class b (ORNBV) Related Businessweek News

No Related Businessweek News Found

orion oyj-class b (ORNBV) Details

Orion Oyj engages in the development and manufacture of pharmaceuticals, active pharmaceutical ingredients (APIs), and diagnostic tests worldwide. The company operates in two segments, Pharmaceuticals and Diagnostics. The Pharmaceuticals segment develops, manufactures, and markets pharmaceuticals and APIs. This segment provides proprietary drugs in the areas of central nervous system, oncology and critical care, and pulmonary care; generic prescription drugs, as well as self-care products, such as non-prescription medicines, basic ointments, and vitamins; proprietary and generic veterinary drugs; and APIs for generic and proprietary drugs, as well as offers contract manufacturing services for APIs. This segment also markets and sells veterinary drugs manufactured by other international companies. The Diagnostics segment develops, manufactures, and markets in vitro diagnostic test systems and tests for diagnosing diseases and monitoring treatment efficacy. The company was founded in 1917 and is headquartered in Espoo, Finland.

3,539 Employees
Last Reported Date: 07/28/15
Founded in 1917

orion oyj-class b (ORNBV) Top Compensated Officers

Chairman of the Executive Management Board, C...
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2014.

orion oyj-class b (ORNBV) Key Developments

Orion Oyj, H1 2015 Earnings Call, Jul 28, 2015

Orion Oyj, H1 2015 Earnings Call, Jul 28, 2015

Orion Corporation Reports Earnings Results for First Half of 2015; Revises Earnings Guidance for the Full Year of 2015

Orion Corporation upgraded the full-year outlook estimate for 2015. Based on the good start for the year the company estimates that the full-year net sales and operating profit will be higher than estimated previously. Net sales is estimated to be at similar level to 2014 (net sales were EUR 1,015 million in 2014). Operating profit is estimated to exceed EUR 260 million. The group's capital expenditure will be about EUR 50 million excluding substantial corporate or product acquisitions. The group's capital expenditure was EUR 57 million in 2014. Previous full-year outlook estimate for 2015, provided on April 24, 2015 was: Net sales will be slightly lower than in 2014 (net sales were EUR 1,015 million in 2014); Operating profit is estimated to exceed EUR 230 million; and the group's capital expenditure will be about EUR 50 million excluding substantial corporate or product acquisitions. The group's capital expenditure was EUR 57 million in 2014. Net sales of the first half of 2015 was EUR 515 million and operating profit of the first half of 2015 EUR 157 million.

Orion Oyj Announces Consolidated Earnings Results for the First Quarter Ended Mach 31, 2015; Revises Earnings Guidance for the Full Year 2015

Orion Oyj announced consolidated earnings results for the first quarter ended Mach 31, 2015. For the quarter, the company reported net sales of EUR 259.9 million compared with EUR 245.0 million for the same period a year ago. Operating profit was EUR 83.1 million compared with EUR 67.4 million for the same period a year ago. Profit before taxes was EUR 82.7 million compared with EUR 66.5 million for the same period a year ago. Profit for the period was EUR 65.7 million compared with EUR 52.6 million for the same period a year ago. Profit attributable to owners of the parent company was EUR 65.7 million or EUR 0.47 per basic and diluted share compared with EUR 52.6 million or EUR 0.37 per basic and diluted share for the same period a year ago. Total net cash flow from operating activities was EUR 62.9 million compared with EUR 59.1 million for the same period a year ago. Investments in property, plant and equipment was EUR 9.0 million compared with EUR 15.6 million for the same period a year ago. Investments in intangible assets was EUR 1.0 million compared with EUR 1.1 million for the same period a year ago. ROE was 57.4% compared with 46.5% for the same period a year ago. The company revised earnings guidance for the full year 2015. The company upgrades the full-year outlook estimate for 2015. The company estimates that the full-year operating profit will be higher than estimated previously. Net sales will be slightly lower than in 2014. Operating profit is estimated to exceed EUR 230 million compared to EUR 200 million estimated earlier. The Group's capital expenditure will be about EUR 50 million excluding substantial corporate or product acquisitions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ORNBV:FH €38.40 EUR +0.37

ORNBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.143.20 CHF +0.30
H Lundbeck A/S kr158.80 DKK -1.80
Hospira Inc $89.44 USD -0.01
Shire PLC 5,730 GBp +50.00
View Industry Companies
 

Industry Analysis

ORNBV

Industry Average

Valuation ORNBV Industry Range
Price/Earnings 24.7x
Price/Sales 5.2x
Price/Book 11.5x
Price/Cash Flow 17.8x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORION OYJ-CLASS B, please visit www.orion.fi. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.